Dulaglutide as a Bridging Therapy Before Insulin for Diabetes Following Pancreatectomy on Congenital Hyperinsulinism.

Motegi S, Adachi M, Nagahara K, Ochi A, Ishida T, Mizuno K

JCEM case reports3 Dec 2025

PMID41347115PMCIDPMC12673381DOI10.1210/jcemcr/luaf281PepBankPUB-41347115

Summary

Hyperinsulinism and postpancreatectomy diabetes (CHI/PPD) refers to diabetes following pancreatectomy to treat hypoglycemia due to congenital hyperinsulinism. Insulin therapy in CHI/PPD may sometimes be challenging because of glucagon deficiency and the dysfunction of the remaining β-cells. In a 16-year-old male patient with CHI/PPD and severe hypoglycemic brain damage, a dulaglutide trial was planned, because some biochemical indices suggested that he was not completely insulin-dependent. Other than transient appetite loss, no adverse events were observed. The patient's hemoglobin A1c level promptly decreased from 6.7% (SI: 49.7 mmol/mol) [reference range, 4.6-6.2% (SI: 26.8-44.3 mmol/mol)] to 5.7%, with temporary, but not persistent, improvement in endogenous insulin secretion. He has been free from exogenous insulin for more than 4 years under dulaglutide. In conclusion, in selected patients with CHI/PPD and reserved β-cell function, dulaglutide may serve as a bridging therapy before insulin introduction.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanCase report or seriesSafety outcome
In an adolescent with postpancreatectomy diabetes, transient appetite loss occurred during dulaglutide treatment.
In plain wordsIn an adolescent with diabetes after pancreatic surgery, temporary appetite loss occurred during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableTransient appetite loss
Study
n = 1
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Other than transient appetite loss, no adverse events were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
In a 16-year-old male patient with CHI/PPD and severe hypoglycemic brain damage, a dulaglutide trial was planned, because some biochemical indices suggested that he was not completely insulin-dependent.
Show in the study text Report a problemFND-4134711501
02HumanCase report or seriesSafety outcome
In an adolescent with postpancreatectomy diabetes, no adverse events other than transient appetite loss were observed during dulaglutide treatment.
In plain wordsIn an adolescent with diabetes after pancreatic surgery, no other adverse events occurred during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableOther adverse events
Study
n = 1
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Other than transient appetite loss, no adverse events were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
In a 16-year-old male patient with CHI/PPD and severe hypoglycemic brain damage, a dulaglutide trial was planned, because some biochemical indices suggested that he was not completely insulin-dependent.
Show in the study text Report a problemFND-4134711502
03HumanCase report or seriesEfficacy outcome
In an adolescent with postpancreatectomy diabetes, HbA1c decreased from 6.7% to 5.7% during dulaglutide treatment.
In plain wordsIn an adolescent with diabetes after pancreatic surgery, HbA1c fell from 6.7% to 5.7% during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Baseline HbA1c
6.7%
before treatment
HbA1c
5.7%
during treatment
Source sentences
Summary
The patient's hemoglobin A1c level promptly decreased from 6.7% (SI: 49.7 mmol/mol) [reference range, 4.6-6.2% (SI: 26.8-44.3 mmol/mol)] to 5.7%, with temporary, but not persistent, improvement in endogenous insulin secretion.
1 context sentence(design, population, supporting numbers)
Summary · context
In a 16-year-old male patient with CHI/PPD and severe hypoglycemic brain damage, a dulaglutide trial was planned, because some biochemical indices suggested that he was not completely insulin-dependent.
Show in the study text Report a problemFND-4134711503
04HumanCase report or seriesEfficacy outcome
In an adolescent with postpancreatectomy diabetes, dulaglutide treatment accompanied temporary but not persistent improvement in endogenous insulin secretion.
In plain wordsIn an adolescent with diabetes after pancreatic surgery, natural insulin secretion improved temporarily during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
MixedEndogenous insulin secretion
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
The patient's hemoglobin A1c level promptly decreased from 6.7% (SI: 49.7 mmol/mol) [reference range, 4.6-6.2% (SI: 26.8-44.3 mmol/mol)] to 5.7%, with temporary, but not persistent, improvement in endogenous insulin secretion.
1 context sentence(design, population, supporting numbers)
Summary · context
In a 16-year-old male patient with CHI/PPD and severe hypoglycemic brain damage, a dulaglutide trial was planned, because some biochemical indices suggested that he was not completely insulin-dependent.
Show in the study text Report a problemFND-4134711504
05HumanCase report or seriesEfficacy outcome
An adolescent with postpancreatectomy diabetes remained free from exogenous insulin for more than 4 years under dulaglutide.
In plain wordsAn adolescent with diabetes after pancreatic surgery needed no external insulin for more than 4 years during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableFreedom from exogenous insulin
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Time without exogenous insulin
> 4 years
under dulaglutide
Source sentences
Summary
He has been free from exogenous insulin for more than 4 years under dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
In a 16-year-old male patient with CHI/PPD and severe hypoglycemic brain damage, a dulaglutide trial was planned, because some biochemical indices suggested that he was not completely insulin-dependent.
Show in the study text Report a problemFND-4134711505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.